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ABSTRACT 
Objectives 
To quantify the epidemiology of bladder cancer in Africa to guide a targeted public health 
response and support research initiatives.  
 
Methods  
We systematically searched publicly available sources for population-based registry studies 
reporting the incidence of bladder cancer in Africa between January 1980 and June 2017. 
Crude incidence rates of bladder cancer were extracted. A Bayesian network meta-analysis 
model was employed to estimate incidence rates. 
 
Results 
The search returned 1,328 studies. Twenty-two studies conducted across 15 African countries 
met our pre-defined selection criteria. Heterogeneity across studies was high (I2=98.9%, 
p<0.001). The pooled incidence of bladder cancer in Africa was 7.0 (95% Credible Interval [CI]: 
5.8-8.3) per 100,000 population in men, and 1.8 (1.2-2.6) per 100,000 in women. The incidence 
of bladder cancer was consistently higher in North Africa in both sexes. Among men, we 
estimated a pooled incidence of 10.1 (7.9-11.9) per 100,000 in North Africa and 5.0 (3.8-6.6) per 
100,000 in Sub-Saharan Africa (SSA). In women, the pooled incidence was 2.0 (1.0-3.0) per 
100,000 and 1.5 (0.9-2.0) per 100,000 in North Africa and SSA, respectively. Incidence rates 
increased significantly among men from 5.6 (4.2-7.2) in the 1990s to 8.5 (6.9-10.1) per 100,000 
in 2010. 
 
Conclusions  
This study suggests a growing incidence of bladder cancer in Africa in recent years, particularly 
among men and in North Africa. This study also highlights the lack of quality data sources and 
collection of essential clinical and epidemiological data in several African countries and this 
maligns public health planning.   
 
 
Keywords: Africa; Bladder cancer; Schistosoma haematobium; Squamous cell carcinoma; 
Transitional cell carcinoma
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1.  Introduction 
Bladder cancer is the ninth most common cancer worldwide, with an estimated 430,000 
new cases and 165,000 deaths in 2012.1  Among the leading cancer sites in Africa, there were 
an estimated 24,437 new cases and 13,268 deaths from bladder cancer in 2012.1 The risks of 
bladder cancer appear to vary across world regions, correlating with smoking and occupational 
exposures to carcinogens in developed countries, and with chronic bladder urothelial irritation 
from Schistosoma haematobium infection in Africa and the Middle East.2 However, this is 
changing as several African countries undergo social and economic development and changes.  
That is, while the histologic sub-type of bladder cancer in most parts of Africa has historically 
been squamous cell carcinoma (SCC) linked to schistosomiasis, a gradual shift to transitional 
cell carcinoma (TCC) linked to increased cigarette smoking and other lifestyle changes 
associated with urbanization and industrialization has been documented.3,4  
While the general awareness of cancer in Africa continues to increase,5 health systems 
are generally fractured and underfinanced and thus cancer screening services supporting early 
cancer diagnosis and prompt treatment are largely unavailable. For those diagnosed with 
cancer, a lack of subspecialty training in oncology and essential cancer medicines results in 
suboptimal management plans and care.6 Ongoing inadequate sanitation and hygiene also 
promote the recurrence of urinary schistosomiasis in many parts of Africa. 
In the presence of suboptimal epidemiological data and limited histological data, this 
study seeks to systematically review and coalesce data on the incidence of bladder cancer in 
Africa to provide a comprehensive epidemiological report that can guide relevant research and 
public health policy in the region. 
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2.  Methods 
2.1  Search strategy and data sources  
We systematically searched Medline, EMBASE, Global Health and African Journals 
Online (AJOL), the International Association of Cancer Registries (IACR) website, WHO African 
Region (AFRO) site, GLOBOCAN studies,7-9 “Cancer Incidence in Five Continents (CI5) 
series”,10 “Cancer in Africa: Epidemiology and Prevention,”5 and Google Scholar for population-
based registry studies between January 1980 through June 2017 reporting the incidence of 
bladder cancer in Africa (Table 1). Reference lists of studies were hand-searched to ensure 
completeness in the data capture.  
2.2  Selection criteria 
Without language restriction, we included population-based registry studies as defined 
by IACR (registries that collect data from different sources in the population on all new cancer 
cases in well-defined populations)10, conducted in Africa that reported crude estimates of the 
incidence of the bladder cancer. For inclusion, a study had to have utilized histologically 
confirmed bladder cancer. We excluded hospital-based reports, studies on non-human subjects, 
reviews, case reports, opinions or editorials.  
2.3       Data extraction 
Data extraction was performed by two independent reviewers (AA and RAD) who 
separately screened studies against the selection criteria (Kappa = 92%). Disagreements were 
resolved by a third reviewer (DA). Data and other relevant information, including location, 
period, design, cancer registry, histological confirmation of diagnosis, data collation methods, 
coding criteria, data ascertainment and modality with which population or person years at risk 
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were generated, mean age (or age range), cancer cases, and crude incidence were extracted 
from each study.  
2.4 Quality criteria 
 Studies were assessed for five quality measures (supplementary material): 
1. The cancer registration process, which grades how the cancer registries collated 
and ascertained their data.  
2. The coding criteria employed across studies was also reviewed to determine if 
the cancer types were reported according to the primary anatomic site 
(topography) or cellular characteristics (morphology—histology, behaviour, and 
grade) using the international classification of diseases (ICD) and oncology (ICD-
O) guidelines.11-13  
3. How population or person-years at risk was generated in each study.  
4. Whether the population covered in each study was representative of the target 
(subnational) and, 
5. national populations.  
Each criterion was scored one (1), with studies graded as high (4-5), moderate (2-3) or low (0-1) 
quality (see Table S1). The quality assessment has been employed in another study.14 
2.5 Data analysis 
A Bayesian network meta-analysis model15,16 was used to estimate the pooled incidence 
rates of bladder cancer per 100,000 population from the raw data. This model was selected due 
to the lack of data across calendar years, age groups, African regions and countries. This 
modeling approach created hierarchical models and included several covariates without leading 
to biases due to over-fitting the data. This is possible as the model is based on a combination of 
information obtained from the bladder cancer data extracted (the likelihood) with a previous 
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known or subjective knowledge (the prior) to generate an update on the process under 
investigation (the posterior probability). In this approach, we used an extension of the random 
effects model17 on the Bayesian meta-analysis models using uninformative priors (i.e., the prior 
was subjective as this was based on a balance of available data). From the Bayesian model, we 
extracted a posterior of plausible estimates as contained within the posterior interval 0.05 to 
0.95, and averaged them to generate the posterior mean estimate. The posterior mean 
estimates corresponded to the pooled incidence rates of bladder cancer, and were obtained by 
averaging over each strata of the posterior distribution of the expectation of likelihood function 
respectively for all Africa (sorted by sex), African regions, countries, study period, and mean age 
of the patients. By doing this, we have eliminated all non-plausible values from the tails of the 
distribution, and averaged only those within the values of the credible interval (CI). To verify that 
the fit of the Bayesian model appropriately summarizes cancer explanatory variables as 
contained in our data set, we conducted a posterior predictive check using (i) graphical 
inspection of the posterior distribution of the model or nodes effects; (ii) graphical inspection of 
the observed data and the one generated by the model (marginal distribution of the response 
variable); (iii) Bayesian tests to verify if the moments of the observed data matches those 
generated by the model; and (iv) the Watanabe-Akaike or widely applicable information criterion 
2 (WAIC2),18 which is a numerical metric used to measure the predictive accuracy of a fitted 
Bayesian model, with a lower WAIC2 score indicating better prediction or model fit.18 All 
statistical analyses were conducted using the package rstan (probabilistic programming 
language) in the R programming language (see Supporting methods).19  
3.  Results 
3.1 Search results 
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The literature search returned a total of 1,328 publications. Out of these, 1,321 
publications were from four databases: PubMed (n=537), EMBASE (n=612), Global Health 
(n=164) and AJOL (n=8). After all of the studies had been collated and duplicates removed, 812 
records remained. Based on article screening, a further 726 studies were excluded, leaving a 
total of 86 full text manuscripts to be assessed. After applying the selection criteria, 64 studies 
were excluded (46 articles did not specify study designs and/ or clarify cancer registration 
process, and 18 studies did not define catchment population). A total of 22 studies were 
retained for this study (Figure 1, Supporting references). 
3.2 Study characteristics 
The retained 22 studies were conducted across 15 African countries, with 8 studies 
retrieved from North Africa, Central Africa (1), East Africa (4), Southern Africa (4), and West 
Africa (5) (Table 2). Study period across all studies ranged from 1986 to 2010. The mean age 
across studies ranged from 36.8 years to 61 years, with subjects mostly in the 50-59-year age 
group (60%), followed by the 40-49-year age group (30%).  Fifteen studies (68%) were graded 
as high quality (Table S1).  
3.3 Bayesian network modelling 
Significant associations were observed between incidence of bladder cancer and 
increasing age, gender and African sub-region (Prob>F = 0.0003, adjusted R-squared = 39.7%). 
All the Bayesian networks models showed agreement with the scale of the observed datasets 
(Figure 2 and Figure 3) however we used Model 6 presented in the supplement due to the 
model fit statistics (Table 3, i.e. has the lowest WAIC2 score), to generate the reported 
estimates (Figure S1).  
3.4 Pooled incidence rate of bladder cancer in Africa 
3.4.1 Continent-wide 
8 
 
Across African regions, variations were observed in the reported incidence of bladder 
cancer, with high heterogeneity estimated across studies (I2=98.9%, p<0.001). The pooled 
crude incidence of bladder cancer in Africa was significantly higher among men compared to 
women, with incidence estimated at 7.0 (95% CI: 5.8-8.3) per 100,000 population per year in 
men, and 1.8 (95% CI: 1.2-2.6) per 100,000 in women (Table 4).  
3.4.2 Regions 
The incidence of bladder cancer was consistently higher in North Africa in both sexes. 
Among men, we estimated a pooled incidence of 10.1 (95% CI: 7.9-11.9) per 100,000 in North 
Africa and 5.0 (95% CI: 3.8-6.6) per 100,000 in Sub-Saharan Africa (SSA). In women, the 
pooled incidence was 2.0 (95% CI: 1.0-3.0) per 100,000 and 1.5 (95% CI: 0.9-2.0) per 100,000 
in North Africa and SSA, respectively. Among men in SSA, Southern Africa had a relatively 
higher incidence at 7.1 (95% CI: 4.7-9.7) per 100,000 followed by West Africa at 4.5 (95% 
CI:2.9-7.3) per 100,000, while the incidence in Central, and East Africa were 3.8 (95% CI: 0.9-
9.4), and 3.5 (95% CI: 2.7-5.4) per 100,000, respectively. Among women, the incidence across 
SSA sub-regions were comparable, with Central, East, Southern and West Africa having 1.3 
(95% CI: 0.4-2.5), 1.7 (95% CI: 1.1-2.5), 1.5 (95% CI:0.8-2.6), and 2.0 (95% CI:1.3-2.9) per 
100,000, respectively (Table 4, Figure 4 and Figure 5).  
3.4.3 Time-trends and age-groups 
Among men, the incidence of bladder cancer increased from 5.6 (95% CI: 4.2-7.2) in the 
1990s to 8.5 (95% CI: 6.9-10.1) per 100,000 in 2010. Among women, a minimal decrease in 
incidence was observed over the same period. Meanwhile, increase in bladder cancer incidence 
was also observed with advancing age among men, with incidence increasing from 4.8 (95% CI: 
1.9-11.9) per 100,000 among persons aged 30-39 years to 13.3 (95% CI: 9.7-15.5) per 100,000 
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among persons aged 60 years and above. The incidence rates were however comparable 
between these age groups among women (Table 4).  
 
4.  Discussion 
This study assembled a range of diverse datasets, mainly population-based cancer 
registries, to provide continent-wide and sub-regional estimates of bladder cancer in Africa. Our 
findings show a significantly higher incidence of bladder cancer among men (7.0 per 100,000) 
compared to women (1.8 per 100,000). This approximately 4:1 disparity in disease incidence 
has been observed in other settings and cohort studies.1,20 In addition, our estimates, which use 
a different statistical method, are comparable to the 2012 GLOBOCAN estimates where the 
male and female bladder cancer incidence was 6.3 and 2.1 per 100,000 population, 
respectively,21 (Table 4). This sex difference is presumably driven to some extent by differences 
in cigarette smoking, although the rates of cigarette smoking is rapidly increasing among both 
sexes across Africa,22-24 as there does not appear to be a sex-specific difference in the 
likelihood of S. hematobium infection.4,25 Dobruch et al26 reported that several biologic and 
epidemiologic factors underlie gender differences in bladder cancer incidence, although women, 
despite a relatively lower incidence rate, particularly present with advanced tumours at 
diagnosis and higher mortality rates owing to delays in urologic evaluations. Meanwhile, we 
observed an increase in the incidence of bladder cancer among men from 5.6 to 8.5 per 
100,000 between 1990 and 2010. 
We noted a consistently higher bladder cancer incidence in North Africa in both sexes. 
Our estimates again are similar to those reported by GLOBOCAN21 and the Global Burden of 
Disease (GBD) collaborators.27 For example, in 2012, GLOBOCAN estimated a bladder cancer 
incidence at 15.1 and 3.0 per 100,000 among men, and 3.2 and 1.6 per 100,000 among 
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women, for North Africa and SSA, respectively;21 and the GBD collaborators also estimated an 
overall incidence of bladder cancer at 8.3 and 5.3 per 100,000, respectively, for the two 
regions27 (Table 4). Indeed, bladder cancer incidence rates in SSA have been reported as 
among the lowest in the world, but the North African estimates are actually comparable with 
incidence rates obtained in Europe (18.0 per 100,000), Middle East (17.2 per 100,000), and the 
Americas (12.9 per 100,000).1,21 Bladder cancer is regarded as the most common malignancy in 
Egypt, constituting over 30% of cancers.28 The higher rates in Egypt, and North Africa generally, 
has been linked to the proximity with the Nile delta region where S. Hematobium infection is 
widespread, and increased cigarette smoking.25 In contrast to other world regions, South-East 
Asia and Western Pacific regions reportedly have lower bladder cancer incidence at 2.0 and 3.5 
per 100,000, respectively.21  
A strength of this paper is a breakdown of cancer incidence across SSA regions, study 
periods, and age groups, which to the best of our knowledge, is the first study on bladder cancer 
incidence offering such detail. We found that the Southern Africa region had a relatively higher 
bladder cancer incidence at 7.1 per 100,000, compared to other SSA regions. While there are 
no clearly comparable estimates, Antoni et al1 noted that women from Malawi had the second 
highest incidence rate of bladder cancer in their study at 9.2 per 100,000. The reasons for these 
regional differences in SSA are not clear, however the presence of several riverine communities 
favouring breeding of Schistosoma species appear to be a key factor.25 
Owing to its association with schistosomiasis and the inability of African countries to 
effectively halt the breeding and transmission of Schistosoma species, bladder cancer has been 
called a ‘neglected tropical disease’.25,29 Although the World Health Organization supported the 
Schistosomiasis Control Initiatives (SCI) introduced across African states in 2002, the 
programme has been ineffective in many SSA regions due to incomplete drug distribution 
resulting in insufficient population coverage, particularly of infants and pre-school children who 
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suffer disproportionately from Schistosoma infection.29 Primary prevention may be the cheapest 
and most effective public health response to bladder cancer in Africa, particularly by intensifying 
eradication programmes for schistosomiasis through widespread praziquantel therapy, provision 
of portable water and appropriate sanitation measures.  
Suboptimal control of primary exposures for bladder disease is further confounded by an 
absence of widespread population-based cancer screening programmes. This contributes to a 
late presentation of cases, usually marked with a low probability of curative treatment.4 Many 
urology centres still lack basic cystoscopy equipment, and there are limited skilled personnel 
and training facilities to support ‘basic’ surgeries like the transurethral resection of bladder tumor 
(TURBT).2,20  
Despite attempts to provide a representative and comprehensive report on the incidence 
of bladder cancer in Africa, the lack of data from many countries remain a major limitation of this 
study. Moreover, many studies were conducted in sub-national population-based cancer 
registries, mainly covering provinces, districts or major cities within a country. This is even 
marked in Central Africa with only one study selected from this region. These geographic and 
demographic differences are reflected in our estimate of heterogeneity (I2>98%, p<0.001). 
Further, variations in study designs, cancer registration, coding and abstracting, and the 
estimation of cancer incidence are important sources of heterogeneity which hinder several 
active disease assessment efforts. Another important source of heterogeneity may be due to the 
differences in tumor subtypes (SCC/TCC), which we could not ascertain from the available data. 
Moreover, we could not specifically describe smoking prevalence and rates of schistosomiasis 
infection across population groups and how these relate to variations in bladder cancer 
incidence in African sub-regions. Another limitation of this study is the inability to estimate age-
standardized rates of bladder cancer incidence on the continent. This is mainly due to the lack 
of data on age from many studies. We could also have missed some important findings by 
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excluding hospital-based studies, however, considering that several hospital-based reports do 
not clearly define population covered or person-years at risk, we believe including these studies 
may affect the overall representativeness of our estimates. 
These limitations aside, our findings offer the closest possible representation of the 
incidence of bladder cancer in Africa considering available data. To augment the contribution of 
our work, we have provided all our data to support future efforts by others. It is our hope that 
these findings may encourage policy redirection and resource allocation towards improved 
primary prevention, early diagnosis, improved research and capacity building targeted at 
bladder cancer on the continent. 
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Table 1. Search terms for studies on bladder cancer in Africa (MEDLINE)* 
 
# Searches 
1  africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ or 
central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial guinea/ 
or gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or rwanda/ or 
somalia/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or lesotho/ or 
malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or zimbabwe/ or africa, 
western/ or benin/ or burkina faso/ or cape verde/ or cote d'ivoire/ or gambia/ or ghana/ or guinea/ or 
guinea-bissau/ or liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ or sierra leone/ or togo/ 
2  exp vital statistics/ or exp incidence/ 
3  (incidence* or prevalence* or morbidity or mortality).tw. 
4  (disease adj3 burden).tw. 
5  exp "cost of illness"/ 
6  exp quality-adjusted life years/ 
7  QALY.tw. 
8  Disability adjusted life years.mp. 
9  (initial adj2 burden).tw. 
10  exp risk factors/ 
11  2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12  exp bladder cancer/  
13  1 and 11 and 12 
*Search terms are for MEDLINE. Searches in other databases are relatively similar. 
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TABLE 2. Study characteristics 
Author* Country Study 
period 
African 
region 
Registry Registry data collation methods Quality 
grading 
Cases 
(male) 
Incidence 
rate/ 
100000 
(male) 
Cases 
(female) 
Incidence 
rate/ 
100000 
(female) 
Echimane et al.  Cote 
d'Ivoire 
1995-
1997 
West Abidjan Cancer Registry 
(population-based) 
Data were actively collated from 
public and private hospitals and 
pathology laboratories 
Moderate 23 2.2 18 1.8 
Bah et al.  Gambia 1988-
1997 
West Gambia National Cancer 
Registry (population-
based) 
Data were actively collated from 
public and private hospitals and 
pathology laboratories 
High 21 1 - - 
Sighoko et al.  Gambia 1998-
2006 
West National Population-
based Cancer Registry 
Data were actively collated from 
public and private hospitals and 
pathology laboratories 
High 29 0.9 8 0.21 
Koulibaly et al. Guinea 1992-
1995 
West Guinea Cancer Registry 
(population-based) 
Active search for cancer cases in 
public and private hospitals, 
pathology services, and autopsy 
reports 
Moderate 25 3.8 7 0.9 
El Mistiri et al. Libya 2003 North Benghazi Cancer 
Registry 
Active searching of hospitals, public 
and private laboratories, and death 
certificates 
High 49 11.7 6 1.3 
El Mistiri et al.  Libya 2004 North Benghazi Cancer 
Registry 
Active searching of hospitals, public 
and private laboratories, and death 
certificates 
High 59 12.4 16 4.5 
Banda et al.  Malawi 1994-
1998 
South Malawi National Cancer 
Registry (population-
based) 
Combination of active and passive 
methods of case finding. The registry 
receives copies of reports on all 
cancer cases diagnosed in a central 
pathology laboratory, registry staff 
regularly visit inpatient wards and 
oncology outpatient clinics of national 
hospital, and seven other private and 
faith-based hospitals in the district. 
 
Moderate 36 4.3 3 0.3 
Somdyala et al.  South 
Africa 
 South Population-based cancer 
registry of the Eastern 
Cape Province, South 
Africa 
Active and passive case finding of 
new cancer cases across health 
centres, district and referral hospitals 
and their laboratories 
High 9 0.6 7 0.3 
Missaoui et al.  Tunisia  1993-
2006 
North The population-based 
cancer registry of the 
centre of Tunisia 
Proactive data collection from the 
pathology units of the public and 
private medical centres, and the 
departments of Radiotherapy, 
Oncology and Haematology of the 
High 478 18.5 4 0.2 
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University Hospital of 
Sousse 
Parkin et al.  Uganda 1991-
2006 
East Kampala Cancer 
Registry (population-
based) 
Data collected from several sources 
within Kyadondo county-- screening 
pathology reports from government 
hospitals and private pathology 
laboratories; and conducting regular 
searches for cancer cases admitted 
or treated in hospitals. 
High 134 2.9 81 1.6 
Wabinga et al.  Uganda 1991-
1997 
East Kampala Cancer 
Registry (KCR) 
Active and passive case finding of 
new cancer cases across public and 
private hospitals and pathology 
laboratories 
High 13 2.5 -` - 
Wabinga et al.  Uganda 1991-
2010 
East Kampala Cancer 
Registry (KCR) 
Active and passive case finding of 
new cancer cases across public and 
private hospitals and pathology 
laboratories 
High 10 2.9 - - 
Chokunonga et al.  Zimbabwe 1993-
1995 
South Zimbabwe National 
Cancer Registry 
Data collated from all public and 
private hospitals and pathology 
laboratories 
High 62 8.9 39 6.9 
Basset et al.  Zimbabwe 1990-
1992 
South Zimbabwe National 
Cancer Registry 
(population-based) 
Data are collected from all hospital 
services inthe city, from pathology 
laboratories (public and private), and 
from death certificates. 
High 68 13.2 43 12.5 
Bayo et al.  Mali 1987-
1998 
West Population cancer 
registry in Bamako, Mali 
Data collated from all public and 
private hospitals and pathology 
laboratories 
High 23 7.5 12 3.2 
Newton et al30  Rwanda 1991-
1994 
Central Population-based cancer 
registry in the southern 
prefecture of Butare, 
Rwanda 
Active and passive case finding of 
new cancer cases across public and 
private hospitals and pathology 
laboratories 
Moderate 5 0.9 3 0.4 
Manraj et al.  Mauritius 1989-
1993 
East National cancer registry Systematic registration of cancer 
cases identified from central 
laboratory of Hospitals, admissions 
registers and discharge résumés 
Moderate 114 4.4 44 1.7 
Fedewa et al.  Egypt 1999-
2002 
North Gharbiah Population-
Based Cancer Registry 
Collated from relevant health 
institutions across the region 
High 977 13.7 232 3.2 
Bouchbika et al.  Morocco 2005-
2007 
North Casablance Registry Greater Casablanca Cancer Registry Moderate 368 6.7 52 0.9 
El Mistiri et al.  Libya 2003-
2005 
North Benghazi Cancer 
Registry 
Active searching of hospitals, public 
and private laboratories, and death 
certificates 
High 174 15.2 26 2.3 
Hamdi Cheriff et 
al.  
Algeria 1986-
2010 
North Population-based 
Cancer Registry of Setif 
Active searching of hospitals, public 
and private laboratories, and death 
certificates 
High 262 10.3 34 1.2 
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Hsairi et al.  Tunisia 1993-
1997 
North Cancer registries of the 
regions of the North, 
Sousse and Sfax 
Active search of hospital and 
laboratory registers in the three 
regions  
Moderate 276 10.7 - - 
Note: Data reported for the last year of study (or single site) when pooled data is not available for multiple year (or site) studies, *see Supplementary material for references. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 
 
Table 3. Comparative data score statistics of the Bayesian models 
Sex 
Model
s 
p-values 
(max) 
p-values 
(min) 
p-values 
(median) 
p-values 
(mean) 
p-values 
(sd) 
Eff. N. of 
parameters 
WAIC
2 
Men 
Model-
1 
0.4 0.6 1.0 0.9 0.2 4.5 137.5 
 
Model-
2 
0.4 0.7 1.0 0.9 0.1 5.3 140.9 
 
Model-
3 
0.4 0.7 1.0 0.9 0.1 6.7 138.7 
 
Model-
4 
0.5 0.6 1.0 0.9 0.3 5.3 138.1 
 
Model-
5 
0.5 0.6 1.0 0.8 0.4 9.7 132.5 
 
Model-
6 
0.5 0.6 0.9 0.8 0.4 28.4 118.0 
Wome
n 
Model-
1 
0.2 0.8 1.0 1.0 0.3 4.7 96.9 
 
Model-
2 
0.2 0.7 1.0 1.0 0.2 5.0 96.5 
 
Model-
3 
0.1 0.8 1.0 1.0 0.2 4.9 95.1 
 
Model-
4 
0.3 0.8 1.0 1.0 0.4 4.5 92.8 
 
Model-
5 
0.3 0.7 1.0 0.8 0.3 7.7 77.2 
 
Model-
6 
0.4 0.7 0.8 0.7 0.4 15.5 70.0 
Note: WAIC2- Watanabe-Akaike or widely applicable information criterion, showing the predictive accuracy of the fitted Bayesian model, with a 
lower WAIC2 score indicating better prediction 18. 
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Table 4. Pooled incidence rate of bladder cancer in Africa 
Data Regions 
Men (incidence per 100,000) Women (incidence per 100,000) 
Current study GLOBOCA
N 2012 
estimate 
GBD 2015 
estimate 
Current study GLOBOCAN 
2012 
estimate 
GBD 2015 
estimate  
Posterior mean 
estimate* (95% CI) 
I2 (%), p 
value 
Posterior mean 
estimate* (95% CI) 
I2 (%), p 
value 
Africa Africa 7.0 (5.8-8.3) 99.0, 0.000 6.3 - 1.8 (1.2-2.6) 95.8, 0.000 2.1 - 
African Region North 10.1 (7.9-11.9) 99.4, 0.000 15.1 13.9 2.0 (1.0-3.0) 97.3, 0.000 3.2 2.6 
 SSA 5.0 (3.8-6.6) 
95.0, 0.000 3.0 7.9 1.7 (1.1-2.5) 94.2, 0.000 1.6 3.2 
 Central 3.9 (0.9-9.4) 
- 2.2  1.3 (0.4-2.5) - 1.3 2.9 
 East 3.5 (2.7-5.4) 
72.8, 0.000 3.3 6.1 1.7 (1.1-2.5) 0.0, 0.748 2.0 2.7 
 South 7.1 (4.7-9.7) 97.7, 0.000 7.5 13.3 1.5 (0.8-2.6) 96.1, 0.000 1.9 5.1 
 West 4.5 (2.9-7.3) 
89.0, 0.000 2.1 8.5 2.0 (1.3-2.9) 89.0, 0.000 1.3 3.2 
Year 1980-1989 6.9 (4.7-9.6) 96.6, 0.000 - - 2.8 (1.0-4.9) 93.2, 0.000 -  
 1990-1999 5.6 (4.2-7.2) 
99.5, 0.000 - - 1.6 (1.0-2.6) 97.0, 0.000 -  
 2000-2010 8.5 (6.9-10.1) 
99.0, 0.000 - - 1.8 (0.9-2.7) 95.8, 0.000 -  
Age 30-39 4.8 (1.9-12.0) 86.5, 0.000 - - 1.9 (1.1-3.3) - -  
 40-49 3.5 (1.9-6.5) 98.7, 0.000 - - 1.7 (0.9-2.6) 93.8, 0.000 -  
 50-59 7.4 (5.9-8.9) 
36.8, 0.208 - - 1.9 (1.1-2.8) 96.6, 0.000 -  
 60-69 13.4 (9.7-15.5) 
99.0, 0.000 - - - 95.8, 0.000 -  
Country Algeria 6.4 (3.3-10.4) 99.8, 0.000 10.8 5.5 1.2 (0.2-2.5) - 1.5 1.7 
 Cote d'Ivoire 4.8 (1.9-12.0) 
- 1.7 5.0 1.9 (1.1-3.3) - 0.5 4.1 
 Egypt 12.4 (7.2-15.4) 
- 21.8 22.4 2.0 (1.0-3.2) - 5.6 4.1 
 Gambia 2.6 (0.9-7.6) 0.0, 0.744 1.1 4.4 1.5 (0.5-2.7) - 0.5 1.8 
 Guinea 4.6 (2.5-8.9) 
- 1.4 10.2 1.6 (0.8-2.8) - 0.5 2.2 
 Libya 12.6 (9.3-14.0) 
47.0, 0.152  15.3 28.4 2.0 (1.0-3.1) 71.5, 0.30 2.3 4.0 
 Malawi 4.8 (2.7-8.7) 
- 8.4 17.4 1.3 (0.4-2.5) - 5.9 8.0 
 Mali 7.4 (4.3-10.4) 
- 7.5 16.6 2.8 (1.0-4.9) - 6.0 5.8 
 Mauritius 5.0 (2.9-8.7) 
- 7.7 9.4 1.7 (1.0-2.8) - 1.8 2.5 
 Morocco 6.9 (4.2-10.3) - 10.8 12.7 1.8 (0.9-3.0) - 1.3 3.2 
 Rwanda 3.9 (0.9-9.4) 
- 4.8 5.7 1.3 (0.4-2.5) - 2.5 2.3 
 South Africa 4.4 (0.8-10.8) 
- 8.2 12.5 1.5 (0.5-2.7) - 2.0 4.9 
 Tunisia 10.4 (5.0-15.5) 
98.1, 0.000 15.3 18.7 1.8 (0.6-3.1) - 1.7 2.0 
 Uganda 3.0 (2.3-5.1) 
0.0, 0.862 0.4 6.2 1.6 (0.7-2.7) - 1.3 2.8 
 Zimbabwe 9.5 (5.2-12.9) 
79.2, 0.028 2.8 20.4 1.7 (0.8-3.0) 84.5, 0.011 3.0 7.7 
*posterior mean est. corresponds to the incidence of bladder cancer estimated in the current study 
